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The aim of our work was to ﬁnd if MCP-1 -2518 (A/G) single nucleotide polymorphism (SNP) inﬂuences somehow the serum
concentrations of high-sensitive CRP (hsCRP) both in patients suﬀering from ischemic heart disease (IHD), myocardial infarction
(MI),anginapectoris(AP),andhypertension(HT)andincontrolgroupofhealthysubjects.Totally,263patientswiththediagnosis
of IHD, out of them 89 with MI, 145 with AP, 205 with HT, and also 67 healthy subjects were included in the study. First, we
estimated the serum levels of hsCRP. We found that patients with AP had signiﬁcantly higher serum level of hsCRP than both
control group of healthy subjects (P = .043) and IHD patients without AP (P = .026). The presence of the mutant G allele
statistically signiﬁcantly correlated with the higher serum levels of hsCRP in patients with IHD (P = .016), AP (P = .004), and
HT (P = .013). Higher correlations were found in men (AP: P = .019; HT: P = .047). In all cases the highest levels of hsCRP were
found both in patients and healthy controls with homozygous GG genotype.
Copyright © 2009 Maria Bucova et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Inﬂammation is a bodily response to tissue injury or
irritationandprimarilyfacilitatesrestorationoftissuehealth.
It can be induced not only by infection but also by processes
associated with any type of cell, tissue, or organ damage.
Chronic low-grade inﬂammation has an important role
also in the ethiology of coronary heart disease (CHD) [1–3].
Several studies have shown that elevated plasma levels of
C-reactive protein (CRP), interleukin-6 (IL-6), ﬁbrinogen
and other soluble inﬂammatory mediators are associated
with both the severity of atherosclerosis and the risk of CHD
[4–7].
There is a possibility that individuals vary in their sen-
sitivity to the general background of intercurrent low-grade
acute-phase stimuli to which everybody is exposed, and that
those who are higher “CRP responders” through genetic
and/or acquired mechanisms are also more susceptible to
progression and complications of atherosclerosis [8].
The aim of our work was to ﬁnd if MCP-1 -2518 (A/G)
single nucleotide polymorphism (SNP) inﬂuences somehow
the tested concentrations of hsCRP both in patients suﬀering
from ischemic heart disease (IHD), myocardial infarction
(MI), angina pectoris (AP), and hypertension (HT) within
the cohort of IHD patients and in control group of
healthy subjects. The reason for our intention was that
the chemokine MCP-1/CCL2 belongs to key inﬂammatory
CC chemokines playing central role in atherosclerosis and
cardiovascular disease development—disease states guided
with chronic low-grade inﬂammation [9–11]. MCP-1/CCL22 Mediators of Inﬂammation
is a potent chemoattractant for monocytes, T cells, and NK
cells. MCP-1 induces the transmigration of CCR2+ mono-
cytes from the circulation, promotes their diﬀerentiation to
lipidladenmacrophages,andcontributestotheproliferation
of arterial smooth muscle cells. This chemokine plays a dual
role in myocardial ischaemia. In addition to several negative
roles in the process of atherosclerosis, thrombotic occlusion
of coronary artery, and in the process of reperfusion, this
chemokine protects myocytes from hypoxia-induced cell
death and has also positive eﬀect in myocardial infarct
healing [12, 13].
2.MaterialsandMethods
2.1. Patients and Controls. Our case control study with
determined MCP-1 polymorphism comprised 263 patients
with IHD (118 males/145 females, mean age 61.52 ±
10.173/64.16 ± 7.543; P = .02), out of them 89 with MI
(55 males/34 females, mean age 59.71±10.031/64.62±6.448
years; P = .006) as well as 145 with angina pectoris (AP)
(59 males/86 females, mean age 60.71 ± 9.837/64.09 ± 7.575
years, P = .028). The control group comprised of 67 healthy
subjects from a region Velky Lom in middle Slovakia (36
males/31 females, mean age 50.33 ± 10.690 years/49.71 ±
9.353 years. P = .802). They have the same MCP-1 gene
prevalence as healthy subjects from whole Slovakia tested
before [10, 14]. Patients and control subjects were unrelated
and of Caucasian origin. The study was approved by the
local Ethics Committee (Faculty of Medicine Comenius
University, Bratislava), and all subjects signed an informed
consent.
Theoriginalcohortofpatientswasenrolledin1999-2000
for the Homocystein Study. Patients with ischemic heart
disease were recruited from cardiological register of Cardi-
ological laboratory of the second Department of Internal
Medicine, Comenius University in Bratislava (standardized
mortality 9.8), cardiological registers of two specialists in
Nove Zamky (stardardized mortality 10.4), and one register
in Velky Lom (standardized mortality 12.6). Randomization
was made according to random tables by independent
researchers. Basic characteristics (structure of sex, age, and
diseases) were analyzed in both groups (patients recruited
into project and patients excluded). Subjects in whom
ischemic heart disease (according to below mentioned cri-
teria) was diagnosed were considered as patients; apparently
healthy subjects were considered as controls.
Ischemicheartdisease(IHD)wasdeﬁnedasdocumented
myocardial infarction (hospitalization or coronarography),
or presence of documented typical angina pectoris (ECG or
Holter) or documented silent ischemia (ECG, Holter, ECG
or exercise test), or pathological ﬁnding on coronary arteries
during selective coronarography or other interventions.
Typical angina pectoris was deﬁned as substernal chest
discomfort with a characteristic quality and duration that
is provoked by exertion or emotional stress and is relieved
by rest or nitroglycerin [15]. It was also documented by
ECG ST segment deviation (exercise test, Holter, or ECG at
rest) reacting to antianginal therapy. Arterial hypertension
was deﬁned as increased blood pressure ≥140/90mmHg
measured using standard protocol or normotension on
antihypertensive therapy. Blood pressure was measured in a
separate quiet room after 5 minutes in sitting position three
times by sphygnomanometer using auscultatory method.
Cardiovascular symptomatology in control subjects was
evaluated according to the standard Rose questionnaire [16]
and, additionally, in 55% of control subjects by exercise
electrocardiography.
Complete personal and medical history was taken by
qualiﬁed physicians, who underwent training to obtain stan-
dardized data. Analyzed parameters included whole blood
count, complete lipid proﬁle (total cholesterol, triglycerides,
apoprotein B, apoprotein AI, high-density lipoprotein-
cholesterol, low-density lipoprotein-cholesterol), glucose,
total antioxidant status, homocysteine and vitamins B status,
inﬂammatory markers, and several oxidative stress parame-
ters.
2.2. Assessment of MCP-1 -2518 SNP. Genomic DNA was
extracted using a standard salting out procedure [17]. MCP-
1 wild-type (A) and mutant (G) alleles were typed by
polymerase chain reaction using sequence speciﬁc primers
(PCR-SSP). Two reaction formats with speciﬁc reactions
either to A or G allele of the MCP-1 -2518 SNP were used,
and an internal control was adopted from phototyping [14].
The sequences of speciﬁc primers were allele A, forward:
5 GTG GGA GGC AGA CAG CTA; allele G, forward: 5  GTG
GGA GGC AGA CAG CTG; constant reverse: 5 TGA GTG
TTC ACA TAG GCT TC. The PCR mixture was according to
Phototyping [18]. PCR ampliﬁcation was carried out using a
PTC-100ThermalCycler(MJResearch,Inc.,Waltham,Mass,
USA). The cycling protocol was described earlier [19]. MCP-
1 -2518 genotypes were assessed from the presence/absence
of PCR amplicons speciﬁc to the particular alleles in a
standard 2% agarose gel stained with ethidium-bromide.
2.3. CRP Level Determination. The serum level of CRP
in patients and control subjects was determined turbidi-
metrically by an ADVIA instrument (Bayer Corporation,
Tarrytown, New York, USA) with reagents from Randox
Laboratories, Ltd. (Crumlin, UK).
2.4. Statistics. The populations were tested for conformity
to the Hardy-Weinberg equilibrium using a 2 × 2 χ2 test
between observed and expected numbers. Levels of hsCRP
betweencontrolsand(sub)groupsofpatientswerecompared
by Mann-Whitney U-test. The association of genotypes with
the levels of hsCRP was statistically evaluated by Kruskal-
Wallis test, and for comparison of hsCRP concentrations to
particular genotypes the Bonferonni Post Hoc test was used.
A P-value <. 05 was considered to be signiﬁcant.
3. Results
3.1. Serum Levels of hsCRP in Patients with IHD, MI, AP, and
HT, and in Control Group of Healthy Subjects. The serum
levels of hsCRP in patients with estimated diagnosis wereMediators of Inﬂammation 3
Table 1: Serum levels of hsCRP in patients with IHD, MI, AP, and hypertension and in control group of healthy subjects. Legend: IHD:
ischemic heart disease; MI: myocardial infarction; AP: angina pectoris; HT: hypertension.
Estimated groups Number of subjects hsCRP (ng.ml
−1) ± SD Signiﬁcance
(Mann-Whitney) (P =)
Controls without HT 62 2.149 ±2.348
IHD 299 2.607 ±2.663 .199
MI 102 2.671 ±2.891 .228
AP 159 2.899 ±2.794 .043
HT (in IHD patients) 229 2.541 ±2.479 .214
Angina pectoris versus IHD+AP− 159/140 2.899 ±2.794
.026
2.275+ 2.474
Table 2: Serum levels of hsCRP in patients with IHD, MI, AP, and HT in relation to the tested MCP-1 -2851 (A/G) SNP. Legend: IHD:
ischemic heart disease; MI: myocardial infarction; AP: angina pectoris; HT: hypertension; Sg.: signiﬁcance; SD: standard deviation.
Estimated groups Number of subjects Genotype hsCRP (ng.ml
−1) ± SD
(men + women)
Compared genotypes Bonferroni’s post
hoc test (P =)
Controls 37 AA 2.323 ±2.4126 AA : AG 1.000
25 AG 2.650 ±1.9339 AG : GG 1.000
5G G 2.992 ±4.7494 AA : GG 1.000
Sg.: P = .787
IHD 142 AA 2.449 ±2.6945 AA : AG 1.000
93 AG 2.423 ±2.2847 AG : GG .022
28 GG 4.004 ±3.8814 AA : GG .018
Sg.: P = .016
MI 50 AA 2.573 ±2.7242 AA : AG 1.000
29 AG 2.503 ±2.5237 AG : GG .786
10 GG 3.682 ±4.1514 AA : GG .792
Sg.: P = .494
AP 83 AA 2.560 ±2.6080 AA : AG 1.000
40 AG 2.615 ±2.5862 AG : GG .003
22 GG 4.833 ±3.9930 AA : GG .012
Sg.: P = .004
HT 111 AA 2.375 ±2.5071 AA : AG 1.000
72 AG 2.308 ±2.1775 AG : GG .016
22 GG 4.054 ±3.6638 AA : GG .016
Sg.: P = .013
higher than those in control group of healthy subjects. The
highest levels of hsCRP were found in patients with AP (P =
.043). These levels were statistically signiﬁcantly higher than
those in IHD patients without AP (P = .026) (Table 1).
Hardy-WeinbergEquilibrium. Thehealthycontrolgroupwas
in Hardy-Weinberg equilibrium (HWE) with regard to the
distribution of the MCP-1 -2518 A/G genotypes (P>. 05);
observed MCP-1 -2518 G allele frequency was similar to the
data reported previously from other Caucasian populations
[20]. However, IHD patients were slightly deviated from
HWE due to the higher frequency of GG genotype and
lower frequency of AG heterozygotes (P = .02). Similarly,
subgroups of IHD patients with MI (P = .04) and AP (P =
.00002) were not in HWE.
3.2. Concentrations of hsCRP in the Sera of Patients with IHD,
MI, AP, and HT in Relation to MCP-1 -2851 (A/G) SNP
Polymorphism and to Sex. The tested SNP of MCP-1 gene,
concretely the presence of the mutant G allele, statistically
signiﬁcantly correlated with the higher serum level of hsCRP
in patients with IHD (P = .016; in men: P = .060; in women:
P = .197), AP (P = .004; in men: P = .019; in women:
P = .091) and HT (P = .013; in men: P = .047; in women:
P = .122, Tables 2 and 3).
The association between the serum level of hsCRP with
the tested MCP-1 -2518 (A/G) SNP was not statistically
signiﬁcant either in patients with MI (P = .494) or in healthy
c o n t r o ls u b j e c t s( P = .787).
Bonferroni’s Post hoc Test (Correlations between Individual
Genotypes with the Level of hsCRP in Serum of Patients and4 Mediators of Inﬂammation
Table 3: Serum levels of hsCRP in patients with IHD, MI, AP, and HT in relation to the tested MCP-1 -2851 (A/G) SNP and to sex. Legend:
IHD: ischemic heart disease; MI: myocardial infarction; AP: angina pectoris; HT: hypertension; Sg.: signiﬁcance; SD: standard deviation.
Estimated groups Genotype Serum levels of hsCRP Compared genotypes Bonferroni’s
men/women (ng.ml
−1) ± SD post hoc test
Men Women Men Women
(P =)( P =)
Controls AA (15/22) 1.873 ±2.0712 2.630 ±2.6220 AA : AG 1.000
AG (17/8) 2.085 ±1.5630 3.850 ±2.1950 AG : GG .760
GG (4/1) 3.603 ±5.2527 0.550 ±. AA : GG .598
Sg.: P = .426 P = .338
IHD AA (61/81) 2.402 ±2.3681 2.484 ±2.9305 AA : AG 1.000 1.000
AG (43/50) 2.230 ±2.0841 2.589 ±2.9305 AG : GG .065 .334
GG (14/14) 4.016 ±3.8739 3.993 ±4.0351 AA : GG .093 .224
Sg.: P = .060 P = .197
MI AA (29/21) 2.532 ±2.4858 2.629 ±3.0863 AA : AG 1.000 1.000
AG (18/11) 1.793 ±1.4071 3.665 ±3.4750 AG : GG .143 1.000
GG (8/2) 4.016 ±4.4663 2.345 ±3.3163 AA : GG .467 1.000
Sg.: P = .138 P = .668
AP AA (34/49) 2.508 ±2.2623 2.597 ±2.8456 AA : AG 1.000 1.000
AG (14/26) 2.002 ±1.5980 2.944 ±2.9636 AG : GG .037 .088
GG (11/11) 4.799 ±4.0405 4.866 ±4.1418 AA : GG .026 .255
Sg.: P = .019 P = .091
HT AA (41/70) 2.209 ±1.9115 2.472 ±2.8065 AA : AG 1.000 1.000
AG (27/45) 1.918 ±1.5853 2.541 ±2.4529 AG : GG .090 .133
GG (9/13) 3.820 ±3.1319 4.216 ±4.1089 AA : GG .044 .191
Sg.: P = .047 P = .122
Healthy Subjects). This test showed diﬀerences in the serum
levelsofhsCRPcomparingsubjectswithtypicalgenotypes—
AA : AG, AG : GG, and AA : GG. We found statistically
signiﬁcant diﬀerences in patients with IHD (AG : GG; P =
.022, AA : GG; P = .018), AP (AG : GG; P = .003, AA : GG;
P = .012), and HT (AG : GG; P = .016, AA : GG; P = .016)
(Table 2).
Bonferroni’s Post hoc Test (Correlations between Individual
Genotypes with the Level of hsCRP in Serum of Patients
and Healthy Subjects According to Sex). We revealed high
signiﬁcant correlations in men with AP (AG : GG; P = .037,
AA : GG;P = .026)andinmenwithHT(AA : GG;P = .044)
(Table 3).
4. Discussion
Understanding the factors that directly or indirectly regulate
the CRP release at baseline and during inﬂammation is very
important in context of coronary risk prediction. More sci-
entiﬁc groups studied CRP gene polymorphisms and found
that basal levels of CRP both in patients and healthy controls
are genetically determined and under repeated examination
in healthy subjects relatively stable. Thus understanding
the genetic background of CRP that regulates basal but
also by infection or any type of inﬂammation-induced
concentration of CRP might contribute to stratiﬁcation
of healthy subjects to diﬀerent groups with higher or
lower degree of cardiovascular disease development [21–
24]. D’Aiuto et al. [25] found that patients with homozy-
gous +1444TT allele of CRP gene had signiﬁcantly higher
serum level of CRP induced by inﬂammatory stimulus. The
production of CRP is, except of CRP gene, regulated also
by other genes coding for IL-6, IL-1 beta, and IL-1Ra [26,
27].
The human CRP gene lies on chromosome 1, within a
conserved region that encodes for proteins critical to the
immune system and to intercellular communication [6, 28].
Dupuis et al. [29] found that multiple genes on chromosome
1 may inﬂuence inﬂammatory biomarker levels and may
have a potential role in development of cardiovascular
disease. They hypothesized that production of biomarkers
of vascular inﬂammation is modulated genetically and by
environmental factors.
In the ﬁrst part of our study we compared the serum
levels of hsCRP in patients with IHD, AP, MI, and HT with
the level in control subjects and found that serum levels of
hsCRP in patients with AP were higher than those in control
groupofhealthysubjects(P = .043).Theselevelswerehigher
also in comparison to IHD patients without AP (P = .026)
(Table 1).
The tested MCP-1 -2518 (A/G) SNP, concretely the
presence of the mutant G allele, statistically signiﬁcantly
correlated with the higher serum level of hsCRP in patients
withIHD(P = .016),AP(P = .004),andHT(P = .013),andMediators of Inﬂammation 5
in all cases higher correlations were found in men (Table 3).
Comparing subjects with typical genotypes (AA, AG, GG),
Bonferroni’s post hoc test showed diﬀerences in the serum
levels of hsCRP in patients with IHD, AP, and HT. The
highest levels of hsCRP were associated with the presence of
homozygous GG genotype (Table 2). The test also revealed
high signiﬁcant correlations of the presence of G allele with
the elevated levels of hsCRP in men with AP and HT.
5. Conclusion
Our results suggest that MCP-1 -2518 (A/G) SNP is asso-
ciated with the level of hsCRP in patients with ischemic
heartdisease,anginapectoris,andhypertensionintheSlovak
population. The highest levels of hsCRP were found in
subjects with homozygous GG genotype.
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